Cargando…
A novel thiol-saccharide mucolytic for the treatment of muco-obstructive lung diseases
BACKGROUND: Mucin disulfide cross-links mediate pathologic mucus formation in muco-obstructive lung diseases. MUC-031, a novel thiol-modified carbohydrate compound, cleaves disulfides to cause mucolysis. The aim of this study was to determine the mucolytic and therapeutic effects of MUC-031 in sputu...
Autores principales: | Addante, Annalisa, Raymond, Wilfred, Gitlin, Irina, Charbit, Annabelle, Orain, Xavier, Scheffler, Aaron Wolfe, Kuppe, Aditi, Duerr, Julia, Daniltchenko, Maria, Drescher, Marika, Graeber, Simon Y., Healy, Anne-Marie, Oscarson, Stefan, Fahy, John V., Mall, Marcus A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10209473/ https://www.ncbi.nlm.nih.gov/pubmed/37080569 http://dx.doi.org/10.1183/13993003.02022-2022 |
Ejemplares similares
-
An optimized protocol for assessment of sputum macrorheology in health and muco-obstructive lung disease
por: Völler, Mirjam, et al.
Publicado: (2022) -
Thiol drugs decrease SARS-CoV-2 lung injury in vivo and disrupt SARS-CoV-2 spike complex binding to ACE2 in vitro
por: Khanna, Kritika, et al.
Publicado: (2021) -
Role of mucolytics in the management of COPD
por: Poole, Phillippa J
Publicado: (2006) -
Penicillin in Muco-Purulent Conjunctivitis
por: Puttanna, S. T.
Publicado: (1951) -
Treatment of Muco-Membranous Colitis
Publicado: (1904)